Allergan (AGN) Dips as FDA Approves Sientra Silimed-Brand Implants
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
Allergan, Inc. (NYSE: AGN) is ticking lower today following a release from competitor Sientra that it has received FDA approval of its portfolio of Silimed-brand silicone breast implants.
Shares are down 0.3 percent on the session Friday after being up as much as 0.8 percent on the session.
Shares are down 0.3 percent on the session Friday after being up as much as 0.8 percent on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Grey Matters Achieves Final Major Milestone; Receives Radioactive Materials License from State of Florida for its Flagship NovaScan Neuroimaging Clinics™ Location
- FDA grants Nuvation Bio fast track status for brain cancer drug
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
